{"disease":{"id":"refractory-lymphoid-malignancy","name":"refractory lymphoid malignancy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02175433","title":"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}